Statement on Glucagen Hypokit supply 2 August 2023 Novo Nordisk has notified the Therapeutic Goods Administration that the Glucagen Hypokit is currently in a shortage that will last until 30 September 2023. The Glucagen Hypokit is used to treat severe hypoglycaemia where a person is unconscious or unable to take oral hypo treatments. If a person has a severe hypo and you don’t have a Hypokit you need to call 000 immediately. Diabetes Australia is working with the diabetes sector and the TGA to ensure people at highest risk are prioritized access to available supply. The TGA have also activated Section 19A provisions and is arranging imports of Hypokits from other countries. If you have concerns please talk to someone from your diabetes healthcare team.
Media releases 18 June 2026 Hope for Australians living with cystic fibrosis and diabetes as new research targets breakthrough treatment A leading diabetes and respiratory researcher is investigating whether a breakthrough cystic fibrosis treatment could change the course of a serious form of diabetes affecting Australians living with cystic fibrosis. Continue Reading
News 27 May 2026 Tzield listing a game-changer for early-stage type 1 diabetes The first new therapy for type 1 diabetes in nearly a century, which works to delay the need for insulin therapy in type 1 diabetes, has been approved for use in Australia by the Therapeutic Goods Administration. Continue Reading
Blog 27 May 2026 How diabetes, depression, anxiety, and medicines are connected People with diabetes can be depressed or anxious more often than people without diabetes. Studies show that when you have diabetes, you are almost twice as likely to be depressed, regardless of the type of diabetes. Continue Reading
